Acuta Capital Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Acuta Capital Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-170,000	Closed	-$4.32M	–	61
2020 Q2	$4.32M	Sell	170,000 -86,500	-34%	-$1.86M	1.25%	29
2020 Q1	$4.71M	Sell	256,500 -131,000	-34%	-$2.55M	2.28%	18
2019 Q4	$8.54M	Buy	+387,500	New	+$7.8M	2.11%	15
2019 Q3	–	Sell	-384,500	Closed	-$6.06M	–	37
2019 Q2	$6.06M	Buy	384,500 +55,675	+17%	+$757K	2.15%	19
2019 Q1	$4.82M	Buy	+328,825	New	+$3.78M	2.29%	17

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Acuta Capital Partners's DRNA Position: Q3 2020 in Review

Acuta Capital Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 170,000 shares — an estimated $4.32M sold.

Acuta Capital Partners first reported a position in DRNA in Q1 2019 and held it in 5 quarters. The position peaked at $8.54M in Q4 2019. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

Acuta Capital Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Acuta Capital Partners sold 170,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $4.32M.
Acuta Capital Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 5 quarters.
Acuta Capital Partners's Dicerna Pharmaceuticals, Inc. position peaked at $8.54M in Q4 2019.
172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.